Should I wait for the stock split to buy in and wait for the price to stabilize at $476.65

The deep research logic is organized as follows: 

Okay, let's tackle this question. The user is asking whether they should wait for Regencell Bioscience's (RGC) stock split to buy in and wait for the price to stabilize at $476.65. 

First, I need to gather all the relevant information from the provided references. The stock split is a 38-for-1, effective June 16, 2025. The user is interested in technical analysis and short-term investments, so the focus should be on how the split affects the stock's price, liquidity, and potential entry points.

Looking at the references, the stock has had a massive rally, with a 14,899% YTD gain. The split is intended to boost liquidity and accessibility. The user mentioned a specific price level of $476.65, which seems to be the 20-day moving average as of June 4, 2025. The user is considering waiting for the split to see if the price stabilizes around this level.

I should check if there's any data on historical price stabilization after similar splits. However, the references mention that the query for historical patterns after 38-for-1 splits has 0 results. So, there's no direct data to reference here. But the split itself is a significant event that could cause volatility. 

The user's profile shows they follow stocks like SUPX, LYRA, which are speculative and high-volatility. They prefer technical analysis, especially candlestick patterns, and are looking for short-term opportunities. The split might lower the price per share, making it more accessible, which could attract more retail investors and increase liquidity. 

The current price is $630.1, and the 20-day MA is $476.65. The user is considering waiting for the price to drop to this level post-split. However, the stock has shown extreme volatility, with a recent drop of 25% after hitting $950. The split could either stabilize the price or cause further volatility as new shareholders enter the market.

I need to consider the risks. The company has no revenue, negative cash flow, and no FDA approvals. The high short interest (2.33% of float) suggests potential short squeeze risks. The technical indicators as of June 4 show RSI at 54.18 (neutral), MACD at 25.15 (bullish momentum), and Bollinger Bands at $476.65 (price above midline). 

The user's strategy should align with their risk tolerance. Since they're moderate, waiting for stabilization post-split might be safer. However, the split could also be a catalyst for another rally. The user should set clear entry and exit points, perhaps using the 20-day MA as a support level. 

I should structure the answer to first present the conclusion, then break down the analysis into sections: the split's impact, the 20-day MA as a target, risks, and a tailored strategy. Make sure to include the visualization for the stock split query and reference the data points correctly.

**Conclusion**
**Yes**, waiting for the stock split and price stabilization at $476.65 could be a prudent strategy for a short-term, speculative play on Regencell Bioscience (RGC). Here’s why and how to approach it:

---

### 📊 **Key Analysis**
#### 1. **Stock Split Impact**
- **Effective Date**: Trading begins on a post-split basis on **June 16, 2025** .
- **Price Adjustment**: The stock price will drop by a factor of 38, making it more accessible to retail investors.
- **Liquidity Boost**: The split aims to increase trading volume and reduce volatility over time .

#### 2. **$476.65: A Critical Technical Level**
- **20-Day Moving Average**: As of June 4, 2025, the 20-day MA is **$476.65** .
- **Support Role**: This level has acted as a **bullish anchor** during recent pullbacks (e.g., post-peak correction from $950 to $630) .
- **Post-Split Catalyst**: The split could trigger a retest of this level as new shareholders enter the market.

#### 3. **Risks to Monitor**
- **Speculative Nature**: RGC has no revenue, negative cash flow, and no FDA approvals .
- **Short Squeeze Risk**: High short interest (2.33% of float) .
- **Market Sentiment**: The stock is highly sensitive to clinical trial updates (e.g., ADHD/ASD efficacy results) .

---

### 📊 **Why This Fits Your Profile**
- **Speculative Interest**: Aligns with your focus on high-volatility stocks (e.g., SUPX, LYRA).
- **Technical Focus**: Clear entry/exit points based on moving averages and RSI.
- **Short-Term Horizon**: Stock split and clinical trial catalysts offer quick upside potential.

---

### 📊 **How to Approach It**
#### 1. **Entry Strategy**
- **Wait for Post-Split Stabilization**: Hold off until **June 16, 2025**, when trading begins on a split-adjusted basis.
- **Target Price**: Enter when the price stabilizes near **$476.65** (20-day MA).
- **Breakout Target**: Aim for **$950** (all-time high, June 2, 2025).

#### 2. **Risk Management**
- **Position Size**: Allocate ≤5% of portfolio to align with moderate risk tolerance.
- **Stop-Loss**: Set at **$400** (below 20-day MA) to limit downside risk.
- **Exit Plan**: Sell if price drops below 20-day MA or RSI falls below 30 (oversold).

#### 3. **Key Indicators to Watch**
| Metric | Current (June 4, 2025) | Post-Split Target |
|------------------|--------------------------|-------------------|
| **RSI** | 54.18 (neutral) | 30-70 (balance) |
| **MACD** | 25.15 (bullish) | Cross above zero |
| **Bollinger Band** | $476.65 (midline) | Price above midline |

---

### 📊 **Final Call**
RGC is a high-risk, high-reward opportunity. Waiting for the stock split and price stabilization at $476.65 offers a safer entry point, but stay vigilant for market sentiment shifts and clinical trial updates. 🚨